ESG Report 2023

The Group's business covers pharmaceutical finished products, active pharmaceutical ingredients (APIs), and intermediates, with product pipeline in the fields of endocrine, metabolism, autoimmune, opthalmic, anti-infection, etc. Consistency Evaluation of Generic Drugs The United Laboratories strictly adheres to national pharmaceutical laws, regulations and technical guidelines in its product development efforts. The research team combines the technical requirements of drug marketing applications and the consistency evaluation of generic drugs. They conduct comprehensive research on the pharmaceutical quality and bioequivalence of the drugs to ensure compliance with safety, efficacy, and quality control requirements. In the Year, the Group has successfully completed the consistency evaluation of several generic drugs, including Amoxicillin Capsules (0.5g), Injection Piperacillin Sodium Tazobactam Sodium (2.25g), Injection Meropenem (0.25g, 0.5g), and Ibuprofen Sustained Release Capsules (0.3g). These evaluations ensure that the quality and therapeutic effects of these products are consistent with their reference drugs. The Group's market competitiveness has been gradually enhanced through the consistent evaluation of multiple products. As of now, a total of 18 products from the Group have passed (including deemed approval) the consistency evaluation. The Group will continue to advance the work of generic drug consistency evaluation, providing patients with more high-quality medication options. 17 5.2 Enhancing Medical Accessibility 5.2.1 Chinese Market Products Intermediates & APIs APIs Intermediates Human Pharmaceuticals Animal Healthcare Semi-synthetic penicillins type Cephalosporins type β-lactamase inhibitors type Carbapenems type Antibiotics Diabetes drugs Antiallergic drugs Antiviral drugs Cold/cough suppressants Livestock drugs Poultry drugs Pet drugs Aquatic drugs Finished Products 6-APA T-Octylammonium clavulanate Penicillin G potassium first crystal Ophthalmic drugs Skin drugs for external use Cardiovascular and cerebrovvascular drugs Nervous system drugs, etc Intermediates & APIs covering customers near 200 Animal healthcare covering customers over 300 Health and community clinics 100,000 Finished products covering over Hospitals 40,000 Pharmacies 300,000 The Group is primarily engaged in the research, development, production, and sales of pharmaceutical products, APIs, and intermediates. As one of the leading comprehensive pharmaceutical companies in China, the Group's product portfolio includes human pharmaceuticals and animal healthcare. The United Laboratories has a well-established sales team for intermediates, APIs, and formulations, with a sales network covering all over China. Business progress in domestic market Environmental, Social and Governance Report 2023 The United Laboratories International Holdings Limited